Inclusion Criteria:

          -  Patients must have cHL that has not been previously treated (patients who have
             received one dose [day 1 cycle 1] of standard doxorubicin hydrochloride [adriamycin],
             bleomycin, vinblastine and dacarbazine [ABVD] or doxorubicin hydrochloride,
             vinblastine, dacarbazine [AVD] may be enrolled as long as they completed all the
             required standard of care baseline studies before enrollment and initiate study
             therapy by day 15 cycle 1)

          -  Patients must be appropriate candidates for at least 2 cycles of ABVD or AVD (this
             could include patients ranging from favorable risk early stage disease to poor
             prognosis advanced stage disease)

          -  Patients must have measurable FDG-avid disease defined by standard criteria (Lugano
             2014) and a minimum of 1.0 cm in diameter

          -  Patients must have a FDG-PET-computed tomography (CT) of chest, abdomen, and pelvis
             within 56 days of enrollment

          -  Patients should not have evidence of active central nervous system lymphoma

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0, 1, or 2

          -  Patients must have a left ventricular ejection (LVEF) >= 50% within 56 days of
             enrollment

          -  Patients must have adequate labs within 10 days of treatment unless cytopenia is
             thought to be due to underlying disease

          -  Absolute neutrophil count (ANC) >= 1,500/mm^3 (without transfusion or growth factor
             support)

          -  Platelets >= 100,000/mm^3 (without transfusion or growth factor support)

          -  Serum creatinine < 1.5 mg/dl or creatinine clearance greater than 60/ ml per minute by
             the following formula (all tests must be performed within 28 days prior to
             registration)

          -  Total bilirubin < 1.5 times upper limit of normal

          -  Aspartate aminotransferase (AST) < 2.5 times upper limit of normal

          -  All patients must be informed of the investigational nature of this study and have
             given written consent in accordance with institutional and federal guidelines

          -  Patients must be anticipated to complete at least 2 cycles of chemotherapy

          -  Male subjects should agree to use an adequate method of barrier contraception starting
             with the first dose of study therapy through 120 days after the last dose of study
             therapy

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication; subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year

        Exclusion Criteria:

          -  Patients known positive for human immunodeficiency virus (HIV), or infectious
             hepatitis type B or C

          -  Pregnant or nursing women; men or women of reproductive potential may not participate
             unless they have agreed to use an effective contraceptive method

          -  Patients with other prior malignancies except for adequately treated basal cell
             carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or
             other cancer from which the patient has been disease-free for 5 years or greater,
             unless approved by the protocol chair or co-chair

          -  Patients who have other medical conditions that would contraindicate treatment with
             aggressive chemotherapy (including active infection, uncontrolled hypertension,
             congestive heart failure, unstable angina pectoris, or myocardial infarction within
             the past 6 months, uncontrolled arrhythmia, severe pulmonary disease or requirement of
             supplemental oxygen)

          -  Active ischemic heart disease or congestive heart failure

          -  Concurrent use of other anti-cancer agents or experimental treatments

          -  Known current or prior autoimmune disease with the exception of vitiligo

          -  Active or prior history of pneumonitis that required corticosteroids

          -  Current use of supplemental oxygen

          -  Is known to have received a live vaccine within 30 days prior to the first dose of
             trial treatment